AmerisourceBergen to acquire PharMEDium for $2.5bn

AmerisourceBergen president and CEO Steven Collis said: "The acquisition of PharMEDium strengthens our core business and meaningfully expands our innovative service offerings for health systems.

"PharMEDium is a compelling addition to our business, which allows us to provide differentiated offerings and further increases our ability to drive both value and efficiency for our health systems customers in a way that enhances patient safety and helps improve patient outcomes."

AmerisourceBergen is expecting that the deal will generate about $30m in synergies by fiscal 2018.

The acquisition will enable AmerisourceBergen to widen its business of supplying compounded drugs to hospitals.

PharMEDium CEO William Spalding said: "We are excited about this transaction, which brings together two great brands built on the same strong foundation of patient safety and quality, service excellence and value to our customers."

Subject to regulatory review and other customary closing conditions, the transaction is slated for completion in the first quarter of fiscal 2016.

The sterile to sterile CSPs delivered by PharMEDium are prepared in FDA and state board of pharmacy inspected facilities, using FDA-approved or allowed drugs in finished dosage form and FDA-approved diluents and containers.

Maintaining four compounding facilities, the company provides a broad range of 2,000 SKUs and serves more than 3,000 hospital customers across all 50 states.

Image: The acquisition will generate about $30m in synergies by fiscal 2018. Photo: courtesy of adamr/ FreeDigitalPhotos.net